2026年全球非病毒藥物遞送系統市場報告

近年來，非病毒藥物遞送系統的市場規模迅速擴張。預計該市場規模將從2025年的98.4億美元成長到2026年的112.6億美元，複合年成長率（CAGR）為14.4%。成長要素包括：目前對病毒遞送方式的依賴、對非病毒技術的認知度較低、新興生物製藥的開發、藥物遞送法規結構尚不完善，以及奈米顆粒相關學術研究尚處於起步階段。

預計未來幾年非病毒藥物遞送系統的市場規模將快速成長，到2030年將達到190.7億美元，複合年成長率（CAGR）為14.1%。預測期內的成長預計將受到以下因素的推動：聚合物載體技術的進步、RNA和DNA療法的發展、個人化醫療投資的增加、合約研發生產機構（CDMO）的擴張以及製藥公司與學術機構之間合作的加強。預測期內的關鍵趨勢包括：標靶治療中非病毒遞送平台的廣泛應用、奈米顆粒和脂質體載體的日益普及、對降低免疫反應和提高安全性的重視、個人化醫療和標靶治療的發展、CDMO的擴張以及與學術研究機構合作的加強。

預計未來幾年，對個人化醫療日益成長的需求將推動非病毒藥物遞送系統市場的成長。個人化醫療是一種根據個人基因譜、生活方式和環境因素量身訂做治療方案的醫療方法。由於個人化醫療能夠識別每位患者的疾病根源，從而實現更有效的治療，因此其需求不斷成長。非病毒藥物遞送系統在個人化醫療中發揮著輔助作用，它能夠安全、精準地將藥物和遺傳物質遞送至目標細胞，從而最大限度地降低風險並提高治療的準確性。例如，根據美國非營利組織「個人化醫療聯盟」（Coalition for Personalized Medicine）統計，截至2024年2月，美國食品藥物管理局（FDA）在2023年核准了16種針對罕見疾病患者的新型個人化治療方法，高於2022年的6種。因此，對個人化醫療不斷成長的需求正在推動非病毒藥物遞送系統市場的成長。

在非病毒藥物遞送系統市場中，主要企業正致力於開發先進技術，例如預先最佳化離子化脂質混合物系統，以簡化基於RNA的療法的開發和遞送。預先最佳化離子化脂質混合物系統是一種製劑技術，旨在將RNA分子高效封裝在脂質奈米顆粒內，從而確保基因治療應用中更高的穩定性、有效載荷保護和靶向遞送能力。例如，2024年9月，美國生物技術公司Cytiva宣布推出一款用於RNA遞送的脂質奈米顆粒（LNP）試劑盒，該試劑盒與其NanoAssemblr Ignite和Ignite+平台相容。本系統採用即用型離子化脂質混合物，可快速篩檢RNA酬載並進行有效的遞送檢驗，尤其適用於感染疾病疫苗的開發。它可與自動化微流體平台無縫整合，支援使用GMP級組件進行可擴展生產，並提供通訊協定和概念驗證數據，以幫助用戶從早期發現到臨床評估。

目錄

第1章：執行摘要

第2章 市場特徵

• 市場定義和範圍
• 市場區隔
• 主要產品和服務概述
• 全球非病毒藥物遞送系統市場：吸引力評分及分析
• 成長潛力分析、競爭評估、策略適宜性評估、風險狀況評估

第3章 市場供應鏈分析

• 供應鏈與生態系概述
• 清單：主要原料、資源和供應商
• 主要經銷商和通路合作夥伴名單
• 主要最終用戶列表

第4章：全球市場趨勢與策略

• 關鍵科技與未來趨勢
  • 生物技術、基因組學和精準醫療
  • 工業4.0和智慧製造
  • 數位化、雲端運算、巨量資料、網路安全
  • 人工智慧（AI）和自主人工智慧
  • 物聯網、智慧基礎設施、互聯生態系統
• 主要趨勢
  • 標靶治療中非病毒遞送平台的應用日益增多
  • 奈米顆粒和脂質體載體的應用日益增多
  • 重點在於降低免疫反應、提高安全性
  • 個人化醫療和標靶治療的發展
  • 擴大CDMO與學術研究之間的合作。

第5章 終端用戶產業市場分析

• 製藥公司
• 生技公司
• 學術研究機構
• 合約研發生產組織（CDMO）
• 醫院和診所

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及 COVID-19 疫情對市場的影響。

第7章：全球策略分析架構、目前市場規模、市場對比及成長率分析

• 全球非病毒藥物遞送系統市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
• 全球非病毒藥物遞送系統市場規模、比較及成長率分析
• 全球非病毒藥物遞送系統市場表現：規模與成長，2020-2025年
• 全球非病毒藥物遞送系統市場預測：規模與成長，2025-2030年，2035年預測

第8章：全球市場總規模（TAM）

第9章 市場細分

• 依分子類型
• 生物製藥，小分子藥物
• 依所提供的生物製藥類型
• 核糖核酸（RNA）、去氧核糖核酸（DNA）、蛋白質或胜肽、抗體
• 最終用戶
• 製藥和生物技術公司、學術研究機構、合約開發和生產組織（CDMO）、醫院和診所
• 按類型細分：生物製藥
• 肽類、蛋白質、單株抗體、基於RNA的療法、基於DNA的治療方法
• 按類型細分：小分子化合物
• 化療藥物、抗發炎藥物、抗病毒藥物、抗生素、荷爾蒙

第10章 區域與國別分析

• 全球非病毒藥物遞送系統市場：按地區分類，歷史資料及預測（2020-2025年、2025-2030年預測、2035年預測）
• 全球非病毒藥物遞送系統市場：依國家分類，歷史資料及預測，2020-2025年、2025-2030年預測、2035年預測

第11章 亞太市場

第12章：中國市場

第13章：印度市場

第14章：日本市場

第15章：澳洲市場

第16章：印尼市場

第17章：韓國市場

第18章 台灣市場

第19章 東南亞市場

第20章 西歐市場

第21章英國市場

第22章：德國市場

第23章：法國市場

第24章：義大利市場

第25章：西班牙市場

第26章：東歐市場

第27章：俄羅斯市場

第28章 北美市場

第29章：美國市場

第30章：加拿大市場

第31章：南美市場

第32章：巴西市場

第33章 中東市場

第34章：非洲市場

第35章 市場監理與投資環境

第36章：競爭格局與公司概況

• 非病毒藥物遞送系統市場：競爭格局與市場佔有率，2024 年
• 非病毒藥物遞送系統市場：公司估值矩陣
• 非病毒藥物遞送系統市場：公司概況
  • Evonik Industries AG
  • Cytiva
  • Arcturus Therapeutics Holdings Inc.
  • CureVac NV
  • PolyPid Ltd

第37章 其他大型企業和創新企業

• Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd

第38章：全球市場競爭基準分析與儀錶板

第39章 重大併購

第40章：高潛力市場國家、細分市場與策略

• 2030年非病毒藥物遞送系統市場：提供新機會的國家
• 2030年非病毒藥物遞送系統市場：充滿新機會的細分市場
• 2030年非病毒藥物遞送系統市場：成長策略
  • 基於市場趨勢的策略
  • 競爭對手的策略

第41章附錄

Non-viral drug delivery systems refer to approaches for administering therapeutic agents into the body without the use of viral vectors. These systems employ physical, chemical, or mechanical methods such as nanoparticles, liposomes, and polymer-based carriers to safely transport drugs to specific target sites. They are designed to minimize the risks associated with viral delivery, including immune responses and insertional mutagenesis. This strategy improves treatment effectiveness and enhances patient safety across a wide range of medical conditions.

The main types of molecules delivered through non-viral drug delivery systems include biologics and small molecules. Biologics are therapeutics derived from living sources and include proteins, peptides, monoclonal antibodies, and nucleic acid-based therapies such as ribonucleic acid (RNA) and deoxyribonucleic acid (DNA). The biologic types delivered comprise RNA, DNA, proteins or peptides, and antibodies. The key end users include pharmaceutical and biotechnology companies, academic and research institutions, contract development and manufacturing organizations (CDMOs), as well as hospitals and clinics.

Tariffs have affected the non-viral drug delivery systems market by increasing the cost of imported materials such as specialized polymers, lipids, and nanoparticles. Segments including RNA-based therapeutics and liposome carriers are most impacted, particularly in regions like Asia-Pacific where manufacturing hubs such as China and India face import duties. This has led to higher production costs and adjustments in supply chains. Positively, tariffs are driving local production, innovation in alternative materials, and greater investment in domestic manufacturing capabilities.

The non-viral drug delivery systems market research report is one of a series of new reports from The Business Research Company that provides non-viral drug delivery systems market statistics, including non-viral drug delivery systems industry global market size, regional shares, competitors with a non-viral drug delivery systems market share, detailed non-viral drug delivery systems market segments, market trends and opportunities, and any further data you may need to thrive in the non-viral drug delivery systems industry. This non-viral drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-viral drug delivery systems market size has grown rapidly in recent years. It will grow from $9.84 billion in 2025 to $11.26 billion in 2026 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to reliance on viral delivery methods, limited awareness of non-viral techniques, emerging biologics development, initial regulatory frameworks for drug delivery, early academic research focus on nanoparticles.

The non-viral drug delivery systems market size is expected to see rapid growth in the next few years. It will grow to $19.07 billion in 2030 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to advancements in polymer-based carriers, growth of rna and dna therapeutics, increasing investment in personalized medicine, expansion of contract development and manufacturing organizations (cdmos), rising collaborations between pharma and academic institutions. Major trends in the forecast period include rising adoption of non-viral delivery platforms for targeted therapies, increasing use of nanoparticles and liposome-based carriers, focus on reducing immune response and enhancing safety, growth in personalized medicine and targeted therapeutics, expansion of cdmos and academic research collaborations.

The rising demand for personalized medicines is anticipated to drive the growth of the non-viral drug delivery systems market in the coming years. Personalized medicine is a healthcare approach that customizes treatment based on an individual's genetic profile, lifestyle, and environmental factors. The demand for personalized medicine is increasing because it enables more effective therapies by addressing the specific underlying causes of disease in each patient. Non-viral drug delivery systems support personalized medicine by enabling the safe and precise delivery of drugs or genetic material to target cells, minimizing risks and improving treatment accuracy. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the U.S. Food and Drug Administration approved 16 new personalized therapies for patients with rare diseases, up from 6 approvals in 2022. Therefore, the growing demand for personalized medicines is fueling the growth of the non-viral drug delivery systems market.

Major companies operating in the non-viral drug delivery systems market are concentrating on advanced technologies, such as pre-optimized ionizable lipid mix systems, to simplify the development and delivery of RNA-based therapeutics. A pre-optimized ionizable lipid mix system is a formulation technology designed to efficiently encapsulate RNA molecules within lipid nanoparticles, ensuring enhanced stability, protection of the payload, and targeted delivery for gene-based therapeutic applications. For example, in September 2024, Cytiva, a US-based biotechnology company, introduced an RNA delivery lipid nanoparticle (LNP) kit compatible with its NanoAssemblr Ignite and Ignite+ platforms. This system features a ready-to-use ionizable lipid mix that enables rapid screening of RNA payloads and effective delivery validation, particularly for infectious disease vaccine development. It integrates seamlessly with automated microfluidic platforms, supports scalable manufacturing using GMP-grade components, and provides protocols along with proof-of-concept data to support users from early discovery through clinical evaluation.

In September 2023, SOHM Inc., a US-based pharmaceutical company, acquired ABBIE from CGA 369 for $10 million. Through this acquisition, SOHM enhanced its capabilities in delivering large genetic payloads using integrase-based, non-viral technologies. ABBIE is being developed as an off-the-shelf gene-editing kit, with commercialization planned for 2024 and human trials expected by late 2025. CGA 369 is a US-based biotechnology company specializing in non-viral, integrase-based gene-editing and genetic payload delivery systems.

Major companies operating in the non-viral drug delivery systems market are Evonik Industries AG, Cytiva, Arcturus Therapeutics Holdings Inc., CureVac N.V., PolyPid Ltd, Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd, Curapath Inc.

North America was the largest region in the non-viral drug delivery systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral drug delivery systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-viral drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-viral drug delivery systems market consists of sales of exosomes, cell-penetrating peptides, and nanocrystals. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Viral Drug Delivery Systems Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses non-viral drug delivery systems market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-viral drug delivery systems ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-viral drug delivery systems market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type Of Molecule Delivered: Biologics; Small Molecules
• 2) By Type Of Biologics Delivered: Ribonucleic Acid (RNA); Deoxyribonucleic Acid (DNA); Proteins or Peptides; Antibodies
• 3) By End User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutes; Contract Development And Manufacturing Organizations (CDMOs); Hospitals And Clinics
• Subsegments:
• 1) By Biologics: Peptides; Proteins; Monoclonal Antibodies; RNA-based Therapeutics; DNA-based Therapies
• 2) By Small Molecules: Chemotherapeutics; Anti-inflammatories; Antivirals; Antibiotics; Hormonal Drugs
• Companies Mentioned: Evonik Industries AG; Cytiva; Arcturus Therapeutics Holdings Inc.; CureVac N.V.; PolyPid Ltd; Ethris GmbH; Entos Pharmaceuticals Inc.; Liquidia Technologies Inc.; ReCode Therapeutics Inc.; Enable Injections Inc.; GenEdit Inc.; N4 Pharma Plc; Hopewell Therapeutics Inc.; Tiba Biotech LLC; Vesigen Therapeutics Inc.; Carmine Therapeutics Inc.; Evox Therapeutics Ltd; InnoCore Pharmaceuticals BV; Nanomerics Ltd; DelSiTech Ltd; Curapath Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Non-Viral Drug Delivery Systems Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Non-Viral Drug Delivery Systems Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Non-Viral Drug Delivery Systems Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Non-Viral Drug Delivery Systems Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Industry 4.0 & Intelligent Manufacturing
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Non-Viral Delivery Platforms For Targeted Therapies
  • 4.2.2 Increasing Use Of Nanoparticles And Liposome-Based Carriers
  • 4.2.3 Focus On Reducing Immune Response And Enhancing Safety
  • 4.2.4 Growth In Personalized Medicine And Targeted Therapeutics
  • 4.2.5 Expansion Of Cdmos And Academic Research Collaborations

5. Non-Viral Drug Delivery Systems Market Analysis Of End Use Industries

• 5.1 Pharmaceutical Companies
• 5.2 Biotechnology Companies
• 5.3 Academic And Research Institutes
• 5.4 Contract Development And Manufacturing Organizations (Cdmos)
• 5.5 Hospitals And Clinics

6. Non-Viral Drug Delivery Systems Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Non-Viral Drug Delivery Systems Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Non-Viral Drug Delivery Systems PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Non-Viral Drug Delivery Systems Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Non-Viral Drug Delivery Systems Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Non-Viral Drug Delivery Systems Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Non-Viral Drug Delivery Systems Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Non-Viral Drug Delivery Systems Market Segmentation

• 9.1. Global Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Biologics, Small Molecules
• 9.2. Global Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ribonucleic Acid (RNA), Deoxyribonucleic Acid (DNA), Proteins or Peptides, Antibodies
• 9.3. Global Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Development And Manufacturing Organizations (CDMOs), Hospitals And Clinics
• 9.4. Global Non-Viral Drug Delivery Systems Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Peptides, Proteins, Monoclonal Antibodies, RNA-based Therapeutics, DNA-based Therapies
• 9.5. Global Non-Viral Drug Delivery Systems Market, Sub-Segmentation Of Small Molecules, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Chemotherapeutics, Anti-inflammatories, Antivirals, Antibiotics, Hormonal Drugs

10. Non-Viral Drug Delivery Systems Market Regional And Country Analysis

• 10.1. Global Non-Viral Drug Delivery Systems Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Non-Viral Drug Delivery Systems Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Non-Viral Drug Delivery Systems Market

• 11.1. Asia-Pacific Non-Viral Drug Delivery Systems Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Non-Viral Drug Delivery Systems Market

• 12.1. China Non-Viral Drug Delivery Systems Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Non-Viral Drug Delivery Systems Market

• 13.1. India Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Non-Viral Drug Delivery Systems Market

• 14.1. Japan Non-Viral Drug Delivery Systems Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Non-Viral Drug Delivery Systems Market

• 15.1. Australia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Non-Viral Drug Delivery Systems Market

• 16.1. Indonesia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Non-Viral Drug Delivery Systems Market

• 17.1. South Korea Non-Viral Drug Delivery Systems Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Non-Viral Drug Delivery Systems Market

• 18.1. Taiwan Non-Viral Drug Delivery Systems Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Non-Viral Drug Delivery Systems Market

• 19.1. South East Asia Non-Viral Drug Delivery Systems Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Non-Viral Drug Delivery Systems Market

• 20.1. Western Europe Non-Viral Drug Delivery Systems Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Non-Viral Drug Delivery Systems Market

• 21.1. UK Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Non-Viral Drug Delivery Systems Market

• 22.1. Germany Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Non-Viral Drug Delivery Systems Market

• 23.1. France Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Non-Viral Drug Delivery Systems Market

• 24.1. Italy Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Non-Viral Drug Delivery Systems Market

• 25.1. Spain Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Non-Viral Drug Delivery Systems Market

• 26.1. Eastern Europe Non-Viral Drug Delivery Systems Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Non-Viral Drug Delivery Systems Market

• 27.1. Russia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Non-Viral Drug Delivery Systems Market

• 28.1. North America Non-Viral Drug Delivery Systems Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Non-Viral Drug Delivery Systems Market

• 29.1. USA Non-Viral Drug Delivery Systems Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Non-Viral Drug Delivery Systems Market

• 30.1. Canada Non-Viral Drug Delivery Systems Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Non-Viral Drug Delivery Systems Market

• 31.1. South America Non-Viral Drug Delivery Systems Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Non-Viral Drug Delivery Systems Market

• 32.1. Brazil Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Non-Viral Drug Delivery Systems Market

• 33.1. Middle East Non-Viral Drug Delivery Systems Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Non-Viral Drug Delivery Systems Market

• 34.1. Africa Non-Viral Drug Delivery Systems Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Segmentation By Type Of Biologics Delivered, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Non-Viral Drug Delivery Systems Market Regulatory and Investment Landscape

36. Non-Viral Drug Delivery Systems Market Competitive Landscape And Company Profiles

• 36.1. Non-Viral Drug Delivery Systems Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Non-Viral Drug Delivery Systems Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Non-Viral Drug Delivery Systems Market Company Profiles
  • 36.3.1. Evonik Industries AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Cytiva Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Arcturus Therapeutics Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. CureVac N.V. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. PolyPid Ltd Overview, Products and Services, Strategy and Financial Analysis

37. Non-Viral Drug Delivery Systems Market Other Major And Innovative Companies

• Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd

38. Global Non-Viral Drug Delivery Systems Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Non-Viral Drug Delivery Systems Market

40. Non-Viral Drug Delivery Systems Market High Potential Countries, Segments and Strategies

• 40.1 Non-Viral Drug Delivery Systems Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Non-Viral Drug Delivery Systems Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Non-Viral Drug Delivery Systems Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer